Drug Patents owned by Aaa Usa Novartis

1. List of Locametz drug patents

LOCAMETZ's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11369590 AAA USA NOVARTIS PSMA binding ligand-linker conjugates and methods for using
Aug, 2028

(5 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Mar 23, 2025

Drugs and Companies using GALLIUM GA-68 GOZETOTIDE ingredient

Market Authorisation Date: 23 March, 2022

Treatment: For use after radiolabeling with gallium-68, for positron emission tomography of prostate-specific membrane antigen (psma)-positive lesions in men with prostate cancer

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

LOCAMETZ family patents

26

United States

8

Japan

6

European Union

2

New Zealand

2

China

1

Portugal

1

Hungary

1

Slovenia

1

Hong Kong

1

Israel

1

Poland

1

Australia

1

Denmark

1

Spain

1

Canada

2. List of Pluvicto drug patents

PLUVICTO's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11318121 AAA USA NOVARTIS PSMA binding ligand-linker conjugates and methods for using
Aug, 2028

(5 years from now)

US10406240 AAA USA NOVARTIS PSMA binding ligand-linker conjugates and methods for using
Aug, 2028

(5 years from now)

US10398791 AAA USA NOVARTIS Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
Oct, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 23, 2027

Drugs and Companies using LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN ingredient

NCE-1 date: 2026-03-23

Market Authorisation Date: 23 March, 2022

Treatment: For treatment of adult patients with prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with androgen receptor (ar) pathway inhibition and taxane-based chemotherapy

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

PLUVICTO family patents

33

United States

14

Japan

14

European Union

4

China

4

Australia

3

New Zealand

3

Korea, Republic of

3

Israel

2

Peru

2

Hong Kong

2

South Africa

2

Canada

1

Portugal

1

Singapore

1

Spain

1

Philippines

1

Mexico

1

Morocco

1

EA

1

Tunisia

1

Slovenia

1

Saudi Arabia

1

Hungary

1

Poland

1

Georgia

1

Chile

1

Denmark

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in